AbbVie (ABBV) Stock Price, News & Analysis

$167.94
+1.53 (+0.92%)
(As of 04/22/2024 ET)
Today's Range
$166.92
$169.59
50-Day Range
$161.67
$182.10
52-Week Range
$130.96
$182.89
Volume
5.58 million shs
Average Volume
5.64 million shs
Market Capitalization
$297.36 billion
P/E Ratio
61.52
Dividend Yield
3.69%
Price Target
$177.43

AbbVie MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.77 Rating Score
Upside/​Downside
5.6% Upside
$177.43 Price Target
Short Interest
Healthy
0.74% of Shares Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
-2.34
Upright™ Environmental Score
News Sentiment
0.34mentions of AbbVie in the last 14 days
Based on 45 Articles This Week
Insider Trading
Selling Shares
$67.78 M Sold Last Quarter
Proj. Earnings Growth
8.78%
From $11.16 to $12.14 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.90 out of 5 stars

Medical Sector

21st out of 910 stocks

Pharmaceutical Preparations Industry

7th out of 426 stocks

ABBV stock logo

About AbbVie Stock (NYSE:ABBV)

AbbVie Inc. is a US-based biopharma company with global operations. The company originated as the bio-pharma segment of Abbott Laboratories and was spun off in late 2012. The company officially IPOd on January 2, 2013; contrary to criticisms, the move was solely to protect the parent company from expiring patents. Post-spin, AbbVie emerged as a research-based biopharma that has more than doubled in size. AbbVie, like its parent Abbot Laboratories, is a well-established dividend growth stock.

Over the years, AbbView Inc. has made numerous acquisitions. Among the more notable are ImmuVen, Pharamcyclics and Allergan plc. Allergan plc was an Ireland-based pharmaceutical company focused on health-oriented aesthetic products and is the owner of Botox. Botox accounts for the bulk of the company’s Aesthetics portfolio revenue and about 4% of the net as of 2022. The total revenue in 2021 was $56.20 billion with a 31% operating margin.

Today, AbbVie operates as a diversified multi-national pharmaceutical company with a patient-centric approach to research. It is in business to discover, develop, manufacture and market pharmaceuticals globally but in a way that best serves the needs of patients and the global community.

The company’s original winner, Humira, is still the number one revenue source but the portfolio has been greatly expanded. Other profitable therapies include but are not limited to SKYRIZI for psoriasis, RINVOQ for rheumatoid arthritis and IMBRUVICA and VENCLEXTA for chronic leukemia conditions.

The company is focused on research and has a number of collaborations and partnerships to that end. Among the many avenues of research and innovation are the advancement of precision medicine or pMedicine. PMeds are designed not only to target the specific causes of diseases, often at the genetic level, but the patients that are most likely to benefit from them. Assuming there are 2 highly effective drugs for 1 disease, PMedicine seeks to identify which patients respond better to each.

As of 2022, AbbVie employed more than 50,000 people globally with 21,000 in STEM-related positions. To date, the company had invested more than $50 billion into research through more than 250 partnerships. Partnerships are with universities, medical facilities, research organizations and other pharmaceutical companies. The company’s operations span 20 countries, treating more than 60 million people and 40 conditions annually.

AbbVie has 5 focus areas for its research and products. These are Immunology, Oncology, Neurology, Virology and Eye Care. The company has a robust pipeline of new products that are in some stage of clinical trials. In most cases, trials are underway for multiple indications, including some therapies that have already been approved for 1 or more conditions.

AbbVie is a leader in ESG and sustainability. The company is a member of the Fortune 100 and one of the Fortune 100’s “Best Companies To Work For”. It is a Top 50 Company regarding diversification and a member of the Dow Jones Sustainability World Index and the S&P ESG Index. Among its many positions is sustainable operations so it can deliver life-changing therapies to those who need them most.

ABBV Stock Price History

ABBV Stock News Headlines

Nvidia's AI Tech Part of Novo Nordisk's New Supercomputer (ABBV)
Novo Nordisk and Nvidia have teamed up to develop supercomputers, aiming to accelerate drug discovery development using advanced AI technologies.
$25,000 into $109,616 in two months?
Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…
AbbVie (NYSE:ABBV) Trading 0.2% Higher
Wells Fargo Reaffirms Their Buy Rating on AbbVie (ABBV)
The system that called 2023’s top 7 stocks is at it again…
Look 2023 kind of sucked from a trading standpoint… Despite the market finishing 24% higher…. Just seven stocks did all of the work… Unless you were holding or actively trading those 7 stocks, your trading year probably wasn’t as fruitful as you had hoped… According to my research, my new trading system would have spotted all seven of the “Magnificent stocks” MONTHS before they reached the highs they are trading at today.
AbbVie (ABBV) to Release Earnings on Friday
AbbVie: Through Humira's Crisis Towards Solid Growth
See More Headlines
Receive ABBV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AbbVie and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Ex-Dividend for 2/15 Dividend
1/12/2024
Last Earnings
2/02/2024
Dividend Payable
2/15/2024
Ex-Dividend for 5/15 Dividend
4/12/2024
Today
4/22/2024
Next Earnings (Confirmed)
4/26/2024
Dividend Payable
5/15/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
CUSIP
00287Y10
Employees
50,000
Year Founded
2013

Price Target and Rating

Average Stock Price Target
$177.43
High Stock Price Target
$196.00
Low Stock Price Target
$150.00
Potential Upside/Downside
+5.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.77
Research Coverage
13 Analysts

Profitability

Net Income
$4.86 billion
Pretax Margin
11.51%

Debt

Sales & Book Value

Annual Sales
$54.32 billion
Cash Flow
$16.04 per share
Book Value
$5.78 per share

Miscellaneous

Outstanding Shares
1,770,650,000
Free Float
1,766,220,000
Market Cap
$298.74 billion
Optionable
Optionable
Beta
0.58

Social Links

Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Should I Buy AbbVie Stock? ABBV Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in AbbVie:

  • AbbVie offers a diverse range of pharmaceutical products, including innovative treatments like Skyrizi and Rinvoq, which have shown promising results in treating various diseases.
  • The company has a strong pipeline of drugs in development, indicating potential for future growth and revenue generation.
  • AbbVie's collaboration with reputable companies like Janssen Biotech and Genentech for developing biologics showcases its commitment to innovation and expanding its product portfolio.
  • Recent positive developments in AbbVie's financial performance, coupled with a stable dividend payout, make it an attractive option for income-seeking investors.
  • Considering the current stock price and market trends, AbbVie's stock shows potential for capital appreciation in the near future.

Cons

Investors should be bearish about investing in AbbVie for these reasons:

  • AbbVie faces risks associated with patent expirations of key drugs, which could lead to revenue declines and increased competition from generic alternatives.
  • The pharmaceutical industry is highly regulated, and any changes in regulations or unexpected legal challenges could impact AbbVie's operations and financial performance.
  • Concerns about the potential impact of healthcare reforms or changes in reimbursement policies on AbbVie's profitability may pose risks to investors.
  • Market volatility and macroeconomic factors could affect AbbVie's stock price, leading to fluctuations in investor returns.
  • Investors should carefully monitor any developments related to AbbVie's ongoing legal disputes or regulatory investigations, as these could have negative implications on the company's reputation and financial standing.
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, April 12, 2024. Please send any questions or comments about these AbbVie pros and cons to contact@marketbeat.com.

ABBV Stock Analysis - Frequently Asked Questions

Should I buy or sell AbbVie stock right now?

13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AbbVie in the last year. There are currently 3 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ABBV shares.
View ABBV analyst ratings
or view top-rated stocks.

What is AbbVie's stock price target for 2024?

13 brokerages have issued 1-year price objectives for AbbVie's shares. Their ABBV share price targets range from $150.00 to $196.00. On average, they expect the company's share price to reach $177.43 in the next year. This suggests a possible upside of 5.6% from the stock's current price.
View analysts price targets for ABBV
or view top-rated stocks among Wall Street analysts.

How have ABBV shares performed in 2024?

AbbVie's stock was trading at $154.97 at the beginning of 2024. Since then, ABBV shares have increased by 8.4% and is now trading at $167.94.
View the best growth stocks for 2024 here
.

Are investors shorting AbbVie?

AbbVie saw a drop in short interest during the month of March. As of March 31st, there was short interest totaling 13,120,000 shares, a drop of 10.7% from the March 15th total of 14,690,000 shares. Based on an average trading volume of 5,660,000 shares, the days-to-cover ratio is presently 2.3 days.
View AbbVie's Short Interest
.

When is AbbVie's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, April 26th 2024.
View our ABBV earnings forecast
.

How can I listen to AbbVie's earnings call?

AbbVie will be holding an earnings conference call on Friday, April 26th at 9:00 AM Eastern. Interested parties can register for or listen to the call using this link.

How were AbbVie's earnings last quarter?

AbbVie Inc. (NYSE:ABBV) released its quarterly earnings results on Friday, February, 2nd. The company reported $2.79 earnings per share for the quarter, topping analysts' consensus estimates of $2.76 by $0.03. The company earned $14.30 billion during the quarter, compared to analyst estimates of $14.02 billion. AbbVie had a net margin of 8.95% and a trailing twelve-month return on equity of 162.28%. The firm's revenue was down 5.4% on a year-over-year basis. During the same period in the previous year, the business posted $3.60 EPS.
Read the conference call transcript
.

How often does AbbVie pay dividends? What is the dividend yield for AbbVie?

AbbVie declared a quarterly dividend on Thursday, February 15th. Shareholders of record on Monday, April 15th will be given a dividend of $1.55 per share on Wednesday, May 15th. This represents a $6.20 dividend on an annualized basis and a dividend yield of 3.69%. The ex-dividend date of this dividend is Friday, April 12th.
Read our dividend analysis for ABBV
.

Is AbbVie a good dividend stock?

AbbVie (NYSE:ABBV) pays an annual dividend of $6.20 per share and currently has a dividend yield of 3.73%. The company has been increasing its dividend for 52 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 227.11%. Payout ratios above 75% are not desirable because they may not be sustainable. Based on earnings estimates, ABBV will have a dividend payout ratio of 51.07% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for ABBV.

What guidance has AbbVie issued on next quarter's earnings?

AbbVie issued an update on its FY 2024 earnings guidance on Wednesday, April, 3rd. The company provided EPS guidance of 10.970-11.170 for the period, compared to the consensus earnings per share estimate of 11.190. The company issued revenue guidance of -.

What is Richard A. Gonzalez's approval rating as AbbVie's CEO?

580 employees have rated AbbVie Chief Executive Officer Richard A. Gonzalez on Glassdoor.com. Richard A. Gonzalez has an approval rating of 88% among the company's employees.

What other stocks do shareholders of AbbVie own?
Who are AbbVie's major shareholders?

AbbVie's stock is owned by a number of retail and institutional investors. Top institutional investors include Sumitomo Mitsui Trust Holdings Inc. (0.25%), Raymond James & Associates (0.24%), Guinness Asset Management LTD (0.07%), Global Assets Advisory LLC (0.05%), Ferguson Wellman Capital Management Inc. (0.04%) and Everett Harris & Co. CA (0.03%). Insiders that own company stock include Azita Saleki-Gerhardt, Brian L Durkin, Carrie C Strom, Carrie C Strom, Elaine K Sorg, Henry O Gosebruch, Jeffrey Ryan Stewart, Kevin K Buckbee, Laura J Schumacher, Michael Severino, Nicholas Donoghoe, Perry C Siatis, Richard A Gonzalez, Robert A Michael, Roxanne S Austin, Scott T Reents and Timothy J Richmond.
View institutional ownership trends
.

How do I buy shares of AbbVie?

Shares of ABBV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does AbbVie have any subsidiaries?
The following companies are subsidiares of AbbVie: AbbVie (Gibraltar) Holdings Limited, AbbVie (Gibraltar) Holdings Limited Luxembourg S.C.S., AbbVie (Gibraltar) Limited, AbbVie (Pty) Ltd., AbbVie A/S, AbbVie AB, AbbVie AG, AbbVie AS, AbbVie Australasia Holdings Limited, AbbVie B.V., AbbVie Bahamas Ltd., AbbVie Biofarmacevtska družba d.o.o., AbbVie Biopharmaceuticals GmbH, AbbVie Biopharmaceuticals LLC, AbbVie Biopharmaceuticals Ltd., AbbVie Bioresearch Center Inc., AbbVie Biotech Ventures Inc., AbbVie Biotechnology GmbH, AbbVie Biotechnology Ltd, AbbVie Biotherapeutics Inc., AbbVie Biotherapeutics Limited, AbbVie Central Finance B.V., AbbVie Corp, AbbVie Corporation, AbbVie Deutschland GmbH & Co. KG, AbbVie EOOD, AbbVie Endocrine Inc., AbbVie Endocrinology Inc., AbbVie Farmacéuticos S.A. de C.V., AbbVie Farmacêutica Ltda., AbbVie Finance B.V., AbbVie Finance Corporation, AbbVie Finance LLC, AbbVie GK, AbbVie GmbH, AbbVie Holdings Corporation, AbbVie Holdings Inc., AbbVie Holdings KK, AbbVie Holdings SAS, AbbVie Holdings Unlimited, AbbVie Holdings s.r.o., AbbVie International S.à r.l., AbbVie Investments Limited, AbbVie Investments S.à r.l., AbbVie Ireland Holdings Limited, AbbVie Ireland NL B.V., AbbVie Ireland Unlimited Company, AbbVie Japan Holdings B.V., AbbVie Kft., AbbVie Komplementär GmbH, AbbVie L.L.C., AbbVie L.da, AbbVie Limited, AbbVie Limited Liability Company, AbbVie Logistics B.V., AbbVie Ltd, AbbVie Ltd., AbbVie Manufacturing Management Limited, AbbVie Nederland Holdings B.V., AbbVie Operations Singapore Pte. Ltd., AbbVie Overseas S.à r.l., AbbVie Oy, AbbVie Participações Ltda., AbbVie Pharmaceutical Trading (Shanghai) Co. Ltd., AbbVie Pharmaceuticals B.V., AbbVie Pharmaceuticals GmbH, AbbVie Pharmaceuticals LLC, AbbVie Pharmaceuticals SCA., AbbVie Pharmaceuticals Societe Anonyme, AbbVie Polska Sp. z o.o., AbbVie Productos Farmacéuticos Limitada, AbbVie Products LLC, AbbVie Promoção L.da, AbbVie Pte. Ltd., AbbVie Pty Ltd, AbbVie Purchasing LLC, AbbVie Real Estate Management GmbH, AbbVie Research B.V., AbbVie Resources Inc., AbbVie Resources International Inc., AbbVie Respiratory LLC, AbbVie S. de R.L., AbbVie S.A., AbbVie S.A., AbbVie S.A.S., AbbVie S.R.L., AbbVie S.r.l., AbbVie S.à r.l., AbbVie SA, AbbVie SAS, AbbVie SIA, AbbVie Sarl, AbbVie Sdn. Bhd., AbbVie Sp. z o.o., AbbVie Spain S.L., AbbVie Stemcentrx LLC, AbbVie Trading S.R.L., AbbVie Trustee Company Limited, AbbVie Tıbbi İlaçlar Sanayi ve Ticaret Limited Şirketi, AbbVie UAB, AbbVie UK Biopharmaceuticals Ltd, AbbVie UK Holdco Limited, AbbVie UK Ltd, AbbVie US Holdings LLC, AbbVie US LLC, AbbVie Venezuela B.V., AbbVie Venezuela Holdings B.V., AbbVie Ventures LLC, AbbVie d.o.o., AbbVie s.r.o., Aeropharm Technology LLC, Allergan, BioDisplay Technologies Inc., Fournier Laboratories Ireland Ltd., Fremont Holding L.L.C., Fundación AbbVie, IEP Pharmaceutical Devices LLC, ImmuVen, KOS Pharmaceuticals Inc., Knoll LLC, Knoll Pharmaceutical Company, Life Properties Inc., Mavupharma, Organics L.L.C., Pharmacyclics (Europe) Limited, Pharmacyclics (Shanghai) Management Consulting Services Limited, Pharmacyclics Cayman Ltd., Pharmacyclics Inc, Pharmacyclics LLC, Pharmacyclics Switzerland GmbH, Rowell Laboratories Inc., S.C. AbbVie S.R.L., Sapphire Merger Sub Inc., Stem CentRx, Stemcentrx Cayman Ltd., Suffolk Merger Sub Inc., and Unimed Pharmaceuticals LLC.
Read More
This page (NYSE:ABBV) was last updated on 4/22/2024 by MarketBeat.com Staff

From Our Partners